Published in J Virol on April 02, 2008
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2010) 2.05
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem (2009) 1.61
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol (2010) 1.43
A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog (2010) 1.38
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother (2009) 1.35
Towards a small animal model for hepatitis C. EMBO Rep (2009) 1.34
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One (2010) 1.29
Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology (2014) 1.19
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem (2011) 1.13
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10
Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets. PLoS Pathog (2013) 1.10
A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly. J Virol (2009) 1.07
Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother (2009) 1.03
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc Natl Acad Sci U S A (2010) 1.02
A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility. J Virol (2012) 1.02
Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res (2009) 0.99
Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation. J Virol (2011) 0.98
Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog (2014) 0.98
Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol (2012) 0.97
Simultaneous reduction and digestion of proteins with disulfide bonds for hydrogen/deuterium exchange monitored by mass spectrometry. Anal Chem (2010) 0.97
Lipid metabolism and HCV infection. Viruses (2010) 0.96
Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology (2009) 0.95
A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol Cell (2015) 0.95
Secreted cyclophilin A, a peptidylprolyl cis-trans isomerase, mediates matrix assembly of hensin, a protein implicated in epithelial differentiation. J Biol Chem (2008) 0.94
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother (2012) 0.93
Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein. PLoS One (2012) 0.92
Isoform-specific inhibition of cyclophilins. Biochemistry (2009) 0.92
Barriers of hepatitis C virus interspecies transmission. Virology (2013) 0.92
Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics (2013) 0.92
Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol (2012) 0.92
Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol (2014) 0.91
Anti-HCV drugs in the pipeline. Curr Opin Virol (2011) 0.90
Proof of concept study to assess fetal gene expression in amniotic fluid by nanoarray PCR. J Mol Diagn (2011) 0.90
Cyclophilins as modulators of viral replication. Viruses (2013) 0.88
Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis (2010) 0.88
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother (2015) 0.88
Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother (2011) 0.87
Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A. J Biol Chem (2012) 0.87
Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis (2013) 0.87
Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J Gen Virol (2010) 0.86
Chicken cyclophilin A is an inhibitory factor to influenza virus replication. Virol J (2010) 0.86
Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem Pharmacol (2009) 0.86
Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol (2012) 0.86
Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation. J Gen Virol (2012) 0.85
Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion. Virol J (2011) 0.85
HuR Displaces Polypyrimidine Tract Binding Protein To Facilitate La Binding to the 3' Untranslated Region and Enhances Hepatitis C Virus Replication. J Virol (2015) 0.84
Treating hepatitis C infection by targeting the host. Transl Res (2012) 0.84
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
Cyclophilin E functions as a negative regulator to influenza virus replication by impairing the formation of the viral ribonucleoprotein complex. PLoS One (2011) 0.83
Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses (2010) 0.83
Novel permissive cell lines for complete propagation of hepatitis C virus. J Virol (2014) 0.83
Cyclophilin inhibitors as a novel HCV therapy. Viruses (2010) 0.82
Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses (2013) 0.81
Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus. Viruses (2012) 0.81
Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection. Chem Biol (2015) 0.80
The role of immunophilins in viral infection. Biochim Biophys Acta (2014) 0.80
Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B. PLoS One (2011) 0.80
Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection. Viruses (2012) 0.79
Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis? Viruses (2013) 0.79
Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol (2015) 0.79
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLoS One (2015) 0.78
Insights into the roles of cyclophilin A during influenza virus infection. Viruses (2013) 0.78
Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study. Biomed Res Int (2014) 0.78
Identification of HIV inhibitors guided by free energy perturbation calculations. Curr Pharm Des (2012) 0.77
Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon (2012) 0.76
Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication. World J Hepatol (2016) 0.75
Chaperones in hepatitis C virus infection. World J Hepatol (2016) 0.75
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. PLoS One (2016) 0.75
Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses (2015) 0.75
Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog (2014) 0.75
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Cyclophilin A protects mice against infection by influenza A virus. Sci Rep (2016) 0.75
Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. PLoS One (2016) 0.75
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties. Bioorg Med Chem Lett (2017) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell (1986) 10.38
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature (1988) 7.98
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol (2003) 5.41
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell (2005) 3.91
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Viral RNA replication in association with cellular membranes. Curr Top Microbiol Immunol (2005) 3.18
Quantitative analysis of the hepatitis C virus replication complex. J Virol (2005) 2.91
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell (2005) 2.78
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology (2007) 2.70
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol (2006) 2.31
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 1.95
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J (2006) 1.89
Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol (2005) 1.86
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1997) 1.84
Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem (2003) 1.77
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69
Participation of rab5, an early endosome protein, in hepatitis C virus RNA replication machinery. J Virol (2007) 1.58
Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol (2007) 1.53
Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol (2006) 1.48
X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature (1993) 1.47
The cyclophilin multigene family of peptidyl-prolyl isomerases. Characterization of three separate human isoforms. J Biol Chem (1991) 1.46
Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol (2007) 1.44
Immunophilins: for the love of proteins. Cell Mol Life Sci (2006) 1.40
X-ray structure of a cyclophilin B/cyclosporin complex: comparison with cyclophilin A and delineation of its calcineurin-binding domain. Proc Natl Acad Sci U S A (1994) 1.37
Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci (1997) 1.36
Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure (1997) 1.34
Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J Virol (2006) 1.29
Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol (2004) 1.08
Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A. Proc Natl Acad Sci U S A (1993) 0.93
NMR studies of [U-13C]cyclosporin A bound to human cyclophilin B. FEBS Lett (1991) 0.88
GRP78 induction by cyclosporin A in human HeLa cells. FEBS Lett (1994) 0.87
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol (2007) 1.53
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog (2010) 1.38
Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J Virol (2006) 1.29
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol (2004) 1.08
Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother (2009) 1.03
A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility. J Virol (2012) 1.02
Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res (2009) 0.99
Simultaneous reduction and digestion of proteins with disulfide bonds for hydrogen/deuterium exchange monitored by mass spectrometry. Anal Chem (2010) 0.97
Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology (2009) 0.95
RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. Blood (2013) 0.93
Ana o 1, a cashew (Anacardium occidental) allergen of the vicilin seed storage protein family. J Allergy Clin Immunol (2002) 0.91
The interaction between claudin-1 and dengue viral prM/M protein for its entry. Virology (2013) 0.90
Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One (2013) 0.90
Cyclophilins as modulators of viral replication. Viruses (2013) 0.88
Perfusion affects the tissue developmental patterns of human mesenchymal stem cells in 3D scaffolds. J Cell Physiol (2009) 0.87
Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol (2012) 0.86
Comparisons of RNAi approaches for validation of human RNA helicase A as an essential factor in hepatitis C virus replication. J Virol Methods (2008) 0.85
Ana o 2, a major cashew (Anacardium occidentale L.) nut allergen of the legumin family. Int Arch Allergy Immunol (2003) 0.83
Mapping of a conformational epitope on the cashew allergen Ana o 2: a discontinuous large subunit epitope dependent upon homologous or heterologous small subunit association. Mol Immunol (2010) 0.80
Cloning and characterization of an 11S legumin, Car i 4, a major allergen in pecan. J Agric Food Chem (2011) 0.80
The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One (2012) 0.79
Combining ligand design with photoligation to provide compact, colloidally stable, and easy to conjugate quantum dots. ACS Appl Mater Interfaces (2013) 0.78
Cloning and characterization of 2S albumin, Car i 1, a major allergen in pecan. J Agric Food Chem (2011) 0.78
Effects of processing on immunoreactivity of cashew nut (Anacardium occidentale L.) seed flour proteins. J Agric Food Chem (2008) 0.77
Molecular determinants of nucleolar translocation of RNA helicase A. Exp Cell Res (2007) 0.76
X-ray structure and biophysical properties of rabbit fibroblast growth factor 1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.75
Racing to Uncover the Link between Zika Virus and Microcephaly. Cell Stem Cell (2017) 0.75
Immunoglobulin E-reactive proteins in cashew (Anacardium occidentale) apple juice concentrate. J Agric Food Chem (2008) 0.75
Selection and characterization of drug-resistant HCV replicons in vitro with a flow cytometry-based assay. Methods Mol Biol (2009) 0.75
Engineering pH-gated transitions for selective and efficient double-strand DNA photocleavage in hypoxic tumors. J Med Chem (2011) 0.75